Table 7.
Case summary of MACE
| Group | Age (year)/gender | Target vessel | Follow-up MLD (mm) | Late lumen loss (mm) | ISR (%) | MACE (month) | Reason for revascularization |
|---|---|---|---|---|---|---|---|
| IVUS-guided group | |||||||
| 1 | 54/F | LAD | 1.38 | 1.42 | 50.71 | 6.0 | ECG(+) |
| 2 | 62/F | LCX | 0.99 | 1.51 | 60.40 | 15.0 | Serum marker(+) |
| 3 | 56/M | LAD | 1.10 | 1.21 | 52.38 | 12.0 | ECG(+) |
| 4 | 63/M | LM | 1.45 | 1.54 | 51.51 | 9.0 | ECG(+) |
| 5 | 59/M | RCA | 1.13 | 1.42 | 55.69 | 12.0 | ECG(+) |
| CAG-guided group | |||||||
| 1 | 58/M | LCX | 0.95 | 1.25 | 56.82 | 3.0 | ECG(+) |
| 2 | 68/F | RCA | 1.20 | 1.50 | 56.00 | 6.0 | ECG(+) |
| 3 | 52/M | LM | 1.15 | 1.60 | 58.19 | 9.0 | ECG(+) |
| 4 | 58/M | LAD | 1.02 | 1.78 | 63.58 | 12.0 | Serum marker(+) |
| 5 | 50/F | LAD | 1.15 | 1.40 | 58.19 | 9.0 | ECG(+) |
| 6 | 64/M | LCX | 1.11 | 1.19 | 51.74 | 12.0 | ECG(+) |
| 7 | 63/F | LAD | 1.20 | 1.30 | 52.00 | 15.0 | ECG(+) |
| 8 | 67/M | RCA | ----- | ------ | ------ | 21.0 | Cardiac death(+) |
| 9 | 60/M | LCX | 1.32 | 1.34 | 50.38 | 18.0 | ECG(+) |
| 10 | 63/F | LAD | 1.03 | 1.22 | 54.22 | 15.0 | ECG(+) |
| 11 | 65/M | RCA | 1.33 | 1.53 | 53.50 | 9.0 | ECG(+) |
| 12 | 59/F | LAD | 0.96 | 1.42 | 59.66 | 18.0 | ECG(+) |
| 13 | 60/M | LAD | 1.08 | 1.24 | 53.45 | 12.0 | ECG(+) |
ACEI - angiotensin-converting enzyme; ARB - angiotensin receptor blockers; BMI - body mass index; CAG - coronary angiography; IVUS - intravascular ultrasound; LVEF - left ventricular ejection fraction; F – female; M – male; MLA - minimum lumen area; MACE - major adverse cardiac events